在晚期乳腺癌中使用或不使用Abemaciclib的imlunestrant
Komal L Jhaveri1, Patrick Neven2, Monica Lis Casalnuovo3
1Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York.
The New England journal of medicine
|December 11, 2024
概括
在患有ESR1突变的晚期乳腺癌患者中,imlunestrant改善了无进展生存率. 与imlunestrant和abemaciclib的联合治疗显示出比单独使用imlunestrant更高的疗效.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 伊姆隆斯特兰是一种口服选择性雌激素受体 (ER) 降解剂,旨在持续抑制ER,即使在ESR1突变的癌症中也有效.
- 它针对ER阳性,HER2阴性晚期乳腺癌,该癌症在之前的内分泌治疗中已经进展.
研究的目的:
- 评估与标准内分泌单独治疗相比,imlunestrant在患有ER阳性,HER2阴性晚期乳腺癌的患者中的疗效.
- 评估结合imlunestrant与abemaciclib与imlunestrant单一治疗的疗效.
主要方法:
- 一项第三阶段的开放性试验随机选择了874名患有晚期乳腺癌的患者接受imlunestrant,标准内分泌疗法或imlunestrant-abemaciclib.
- 主要终点包括ESR1突变患者和整体人口的无进展生存期 (PFS),以及比较imlunestrant-abemaciclib与imlunestrant的PFS.
主要成果:
- 与标准治疗 (3.8个月) 相比,在ESR1突变 (5.5个月) 的患者中,imlunestrant显示PFS显著更长.
- 在整体人群中,PFS在imlunestrant (5.6个月) 和标准治疗 (5.5个月) 之间是相似的.
- 与imlunestrant (5.5个月) 相比,imlunestrant-abemaciclib显著改善了PFS (9.4个月),无论ESR1突变状态如何. 3级以上的不良事件在组合疗法 (48.6%) 中较高.
结论:
- 在ESR1突变的晚期乳腺癌患者中,imlunestrant在PFS中提供了显著的益处.
- 在这种患者群体中,imlunestrant和abemaciclib的组合提供了优越的PFS,而不是单独使用imlunestrant.
更多相关视频
13:43Intraductal Delivery and X-ray Visualization of Ethanol-Based Ablative Solution for Prevention and Local Treatment of Breast Cancer in Mouse Models
Published on: April 1, 2022
4.4K
06:15Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
27.3K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:17Drugs for Treatment of Diarrhea-Predominant IBS
147
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
147